EC approves Regeneron’s Lynozyfic for advanced multiple myeloma
Lynozyfic acts as a bispecific antibody, focusing on the B-cell maturation antigen in myeloma cells and activating CD3-expressing T cells to fight cancer
Johnson & Johnson’s TREMFYA gains EC approval for ulcerative colitis
Amgen announces $900m expansion of Ohio manufacturing facility
Pfizer’s sasanlimab plus BCG shows promise in bladder cancer
AbbVie seeks FDA approval for TrenibotE to treat glabellar lines
Daiichi Sankyo seeks approval for Enhertu in Japan for HER2 positive tumours
Analysis
View More
Risks
View MoreSocietal polarisation and its impact on the pharmaceutical industry
Societal polarisation presents significant challenges for the pharmaceutical industry, affecting regulatory landscapes, public trust, innovation, and market dynamics
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry